M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
Shefali S. Verma,Thomas O. Bergmeijer,Li Gong,Jean-Luc Reny,Joshua P. Lewis,Braxton D. Mitchell,Braxton D. Mitchell,Dimitrios Alexopoulos,Daniel Aradi,Russ B. Altman,Kevin P. Bliden,Yuki Bradford,Gianluca Campo,Kiyuk Chang,John H. Cleator,Jean-Pierre Déry,Nadia Paarup Dridi,Israel Fernandez-Cadenas,Pierre Fontana,Pierre Fontana,Meinrad Gawaz,Tobias Geisler,Gian Franco Gensini,Betti Giusti,Paul A. Gurbel,Willibald Hochholzer,Lene Holmvang,Eun Young Kim,Ho-Sook Kim,Rossella Marcucci,Joan Montaner,Joshua D. Backman,Ruth E. Pakyz,Dan M. Roden,Elke Schaeffeler,Matthias Schwab,Jae-Gook Shin,Jolanta M. Siller-Matula,Jolanta M. Siller-Matula,Jurriën M. ten Berg,Dietmar Trenk,Marco Valgimigli,John M. Wallace,Ming-Shien Wen,Michiaki Kubo,Ming Ta Michael Lee,Ryan Whaley,Stefan Winter,Teri E. Klein,Alan R. Shuldiner,Marylyn D. Ritchie +50 more
TL;DR: CYP2C19*2 is the strongest genetic determinant of on‐clopidogrel platelet reactivity, and three novel associations in clinical outcome subgroups are identified, suggestive for each of these outcomes.
Journal ArticleDOI
Stable angina pectoris.
TL;DR: This review deals with a peculiar SCAD population: patients with angina and ‘normal’ coronary arteries, and reviews and critically discusses the novel pharmacological therapies for SCAD patients.
Journal ArticleDOI
Methodological considerations and approach to cross-technique comparisons using in vivo coronary plaque characterization based on intravascular ultrasound radiofrequency data analysis: insights from the Integrated Biomarker and Imaging Study (IBIS).
Gaston A. Rodriguez-Granillo,Jiro Aoki,Andrew T.L. Ong,Marco Valgimigli,C A G Van Mieghem,Eveline Regar,Eugene P. McFadden,P. J. De Feyter,P. W. Serruys +8 more
TL;DR: The methodology used to obtain and analyse IVUS‐VH images and the approach to cross‐correlations with the other techniques are described.
Journal ArticleDOI
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies.
TL;DR: Benefits and risks of prolonging or shortening DAPT duration will be discussed, with a focus on treatment individualization, and an outlook for possible future directions in the field is provided.
Journal ArticleDOI
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis.
Marco Valgimigli,Pieter C. Smits,Enrico Frigoli,Dario Bongiovanni,Jan Tijssen,Thomas Hovasse,Al Mafragi,Willem-Peter T. Ruifrok,D. Karageorgiev,Adel Aminian,Stefano Garducci,Béla Merkely,Helen Routledge,Kenji Ando,José Francisco Díaz Fernández,Thomas Cuisset,Fazila Tun Nesa Malik,Majdi Halabi,Loic Belle,Jehangir N. Din,Farzin Beygui,Atul Abhyankar,Krzysztof Reczuch,Giovanni Pedrazzini,Dik Heg,Pascal Vranckx +25 more
TL;DR: In HBR patients free from recurrent ischemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPt, regardless of PCI or patient complexity.